Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma

Figure 4 Best percentage changes in the sizes of the intrahepatic target lesions of patients from baseline assessed with modified response evaluation criteria in solid tumors. A: Bevacizumab plus sintilimab plus interventional treatment; B: Lenvatinib plus sintilimab plus interventional treatment. The horizontal coordinate represents each patient and the vertical coordinate represents the percentage change in intrahepatic target lesion size from baseline. BeSiIT: Bevacizumab plus sintilimab plus interventional treatment; LeSiIT: Lenvatinib plus sintilimab plus interventional treatment; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.